Welcome to our dedicated page for Doximity SEC filings (Ticker: DOCS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Doximity filings document financial results, material events, governance actions, and capital-structure details for the operator of a digital platform for U.S. medical professionals. Recent Form 8-K disclosures cover quarterly results and related exhibits, finance and legal leadership changes, Regulation FD updates, and annual-meeting voting outcomes.
The company's regulatory record also includes shareholder voting matters tied to its Class A and Class B common stock structure, director elections, auditor ratification, material agreements, and other security-holder matters. These filings describe how Doximity reports operating performance, governance changes, voting mechanics, and formal public-company events.
Doximity, Inc. (DOCS) reported insider activity by its Chief Financial Officer. On 11/04/2025, the officer acquired 20,200 and 2,668 shares of Class A common stock, each labeled as a code C conversion from Class B following option exercises. The option exercises were at $4.12 and $2.21 per share, respectively.
Following these transactions, the officer beneficially owned 369,793 shares of Class A common stock, held directly. Footnotes state Class B shares are convertible into Class A on a one-for-one basis at the holder’s option, with automatic conversion upon certain events. The reported stock options carry expirations on 12/21/2030 and 09/28/2030, with vesting schedules as disclosed.
Doximity, Inc. reported strong quarterly performance. Revenue for the quarter ended September 30, 2025 reached $168.5 million, up from $136.8 million a year ago. Net income was $62.1 million versus $44.2 million, and diluted EPS was $0.31 compared to $0.22. Gross profit rose to $152.1 million while operating income increased to $63.7 million.
Operating cash flow for the six months was $156.0 million. The company ended the quarter with $169.2 million in cash and cash equivalents and $709.1 million in marketable securities. Doximity repurchased and retired 4,496,467 Class A shares for $220.2 million since program inception, with $279.8 million remaining authorized. The company completed the $36.3 million Pathway Medical acquisition, adding $18.7 million of developed technology and $17.0 million of goodwill.
Doximity, Inc. filed an 8-K announcing it issued a press release with financial results for its fiscal quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference.
The information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, under the Exchange Act and is not subject to Section 18 liabilities, nor incorporated into other filings except as expressly referenced. The report was signed by Chief Financial Officer Anna Bryson.
Doximity (DOCS): Director Form 4 filing. On 11/03/2025, the reporting person exercised a stock option for 2,000 shares of Class B Common Stock at an exercise price of $1.54 per share, converted those 2,000 Class B shares into 2,000 Class A shares, and sold 2,000 Class A shares at $66.44 per share pursuant to a Rule 10b5-1 trading plan adopted on November 12, 2024. Following these transactions, Class A Common Stock beneficially owned directly totaled 19,839 shares. The stock option was originally granted on June 10, 2020 and vests in 36 equal monthly installments starting March 27, 2020, with an expiration date of June 9, 2030.
FMR LLC filed Amendment No. 4 to Schedule 13G reporting beneficial ownership of 8,777,627.56 shares of Doximity (DOCS) Class A common stock, representing 6.4%, with a date of event of 09/30/2025.
FMR reports sole voting power over 8,765,947.45 shares and sole dispositive power over 8,777,627.56 shares. Abigail P. Johnson reports sole dispositive power over 8,777,627.56 shares and no voting power. The filing certifies the holdings were acquired and are held in the ordinary course and not to change or influence control.
DOCS: A stockholder filed a Form 144 notice to sell 2,000 shares of common stock with an aggregate market value of $132,880. The filing lists Morgan Stanley Smith Barney as broker, an approximate sale date of November 3, 2025, and NYSE as the exchange.
The shares were acquired via a stock option exercise on November 3, 2025 for cash. Recent activity shows sales of 2,000 shares on October 1, 2025 for $140,020 and 2,000 shares on September 2, 2025 for $133,140. Shares outstanding were 136,400,248.
Doximity, Inc. (DOCS): A director reported multiple transactions on 10/10/2025. The insider exercised 5,000 stock options at an exercise price of $2.21, converted 5,000 shares of Class B Common Stock into Class A Common Stock, and sold 5,000 Class A shares at an average price of $70.84 pursuant to a Rule 10b5-1 trading plan adopted on February 26, 2025.
Following the transactions, the insider reported 19,839 shares of Class A Common Stock held directly. The filing notes that each share of Class B Common Stock is convertible into one share of Class A Common Stock at the holder’s option, and also outlines additional automatic conversion conditions.
Doximity, Inc. (DOCS) insider filing notifies a proposed sale of 5,000 common shares through Morgan Stanley Smith Barney with an aggregate market value of $354,200.00, scheduled for 10/10/2025 on the NYSE. The shares were acquired the same day by stock option exercise and paid in cash. The filing also discloses three earlier sales by the same seller totaling 15,000 shares in 07/11/2025, 08/08/2025, and 09/12/2025 with gross proceeds of $300,200.00, $315,000.00, and $352,500.00 respectively.
The signer affirms they are unaware of undisclosed material adverse information and, by submitting Form 144, is complying with Rule 144 notification requirements for proposed resale of restricted or control securities.
Doximity insiders reported coordinated transactions on 10/01/2025. Reporting person Kira Wampler, a director, sold 2,000 shares of Class A common stock at $70.01 and concurrently acquired 2,000 shares through conversion/exercise activity tied to outstanding Class B shares and stock options. After these transactions the reporting person beneficially owned 19,839 shares of Class A common stock and 466,700 shares of Class B common stock (equivalent to Class A on conversion). The sale executed under a pre-existing Rule 10b5-1 plan adopted on 11/12/2024, and the stock option exercised carries a $1.54 exercise price with a 06/09/2030 expiration for the vested portion.
Form 144 notice for Doximity, Inc. (DOCS): The filer reports a proposed sale of 2,000 shares of common stock through Morgan Stanley Smith Barney with an aggregate market value of $140,020.00, expected to sell on 10/01/2025 on the NYSE. The securities were acquired on 10/01/2025 by stock option exercise and paid in cash. The filing also discloses three prior sales by the same person in the past three months: 2,000 shares on 09/02/2025 for $133,140.00, 2,000 shares on 08/01/2025 for $114,180.00, and 2,000 shares on 07/01/2025 for $121,920.00. The notice includes the standard Rule 144 signature representation regarding material nonpublic information.